CLDX Q2 2018 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-27.8% YoY

Gross Profit

-$19M-676.3% margin

Operating Income

-$17M-610.7% margin

Net Income

-$16M-593.8% margin

EPS (Diluted)

$-1.67

QoQ Revenue Growth

-32.1%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$18M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$178M

Total Liabilities

$50M

Stockholders' Equity

$128M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-27.8%
Gross Profit	-$19M	-$21M	+11.7%
Operating Income	-$17M	-$29M	+41.7%
Net Income	-$16M	-$29M	+42.6%

Revenue Segments

Product Development And Licensing Agreements

$2M60%

Contracts And Grants

$1M40%